A database of FDA approved therapeutic peptides and proteins
ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1001 | Th1001 | Lepirudin | LVYTDCTESGQNLCLCEGSN Full view | 65 | Ia | Hematological,Metabolic | Refludan | Berlex Labs | Sterile, white, freeze-dried powder | Intravenous infusion | Antithrombins and Fibrinolytic Agents | Prothrombin |
1032 | Th1006 | Bivalirudin | FPRPGGGGNGDFEEIPEEYL Full view | 20 | Ia | Hematological,Metabolic | Angiomax | Medicines Co or MDCO | White lyophilized cake in single-use vials | Intravenous infusion | Antithrombins | Prothrombin |
1033 | Th1006 | Bivalirudin | FPRPGGGGNGDFEEIPEEYL Full view | 20 | Ia | Hematological,Metabolic | Angiox | The Medicines Company UK Ltd | Powder for concentrate for solution | Injection | Antithrombins | Prothrombin |
1148 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Advate | N.A. | Powder form | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
1149 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Alphanate | N.A. | Lyophilized powder | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
1150 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Bioclate | Baxter Healthcare Corporation, Hyland Division and Genetics Institute, Inc. | Sterile, nonpyrogenic, off-white to faint yellow, lyophilized powder | Intravenous infusion | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
1151 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Helixate FS | N.A. | Sterile, stable, purified, nonpyrogenic, dried concentrate | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
1152 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Hemofil M | N.A. | Dry concentrate | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
1153 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Hyate:C | N.A. | Powder | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
1154 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Koate-HP | N.A. | Powder | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
1155 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Kogenate FS | N.A. | Powder | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
1156 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Monarc-M | N.A. | Powder | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
1157 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Monoclate-P | N.A. | Lyophilized powder for solution | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
1158 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | ReFacto | N.A. | Lyophilized powder | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
1159 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Xyntha | N.A. | Sterile, nonpyrogenic, preservative-free, freeze-dried powder | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
1193 | Th1025 | Intravenous Immunoglobulin | IGG1:PSALTQPPSASGSLG Full view | 250 | Ia | Immunological | Civacir | N.A. | N.A. | N.A. | Immunosuppressive Agents, Immunologic factors, Anti-infective agents | High affinity immunoglobulin gamma Fc receptor I,High affinity immunoglobulin gamma Fc receptor IB,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc reg |
1194 | Th1025 | Intravenous Immunoglobulin | IGG1:PSALTQPPSASGSLG Full view | 250 | Ia | Immunological | Flebogamma | Instituto Grifols SA | Sterile, clear or slightly opalescent and colorless to pale yellow, liquid | Intravenous infusion | Immunosuppressive Agents, Immunologic factors, Anti-infective agents | High affinity immunoglobulin gamma Fc receptor I,High affinity immunoglobulin gamma Fc receptor IB,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc reg |
1195 | Th1025 | Intravenous Immunoglobulin | IGG1:PSALTQPPSASGSLG Full view | 250 | Ia | Immunological | Gamunex | Talecris Biotherapeutics | Sterile solution | Intravenous infusion | Immunosuppressive Agents, Immunologic factors, Anti-infective agents | High affinity immunoglobulin gamma Fc receptor I,High affinity immunoglobulin gamma Fc receptor IB,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc reg |
1205 | Th1027 | Insulin Regular | A-chain:GIVEQCCTSIC< Full view | 51 | Ia | Genetic/Hormonal | Humulin R | Eli Lilly and Company | Sterile, clear, aqueous, and colorless solution | Subcutaneous injection in the abdominal wall, the thigh, the gluteal region or in the upper arm and Intravenousadministration of Humulin R (insulin (human recombinant)) U-100 is possible under medical supervision. | Antidiabetic Agents | Insulin receptor,Insulin-like growth factor 1 receptor,Retinoblastoma-associated protein,Cathepsin D,Insulin-degrading enzyme,Neuroendocrine convertase 2,Carboxypeptidase E,Neuroendocrine convertase 1,Protein NOV homolog,Low-density lipoprotein receptor-r |
1206 | Th1027 | Insulin Regular | A-chain:GIVEQCCTSIC< Full view | 51 | Ia | Genetic/Hormonal | Novolin R | Novo Nordisk | Sterile, clear, aqueous, and colorless solution | Subcutaneous and Intravenous infusion | Antidiabetic Agents | Insulin receptor,Insulin-like growth factor 1 receptor,Retinoblastoma-associated protein,Cathepsin D,Insulin-degrading enzyme,Neuroendocrine convertase 2,Carboxypeptidase E,Neuroendocrine convertase 1,Protein NOV homolog,Low-density lipoprotein receptor-r |
1275 | Th1040 | Insulin Lispro | A chain:GIVEQCCTSICS Full view | 51 | Ia | Hormonal/Metabolic/genetic | Humalog | Eli Lilly | Sterile, aqueous, clear, and colorless solution | Subcutaneous and Intravenous infusion | Hypoglycemic Agents, Antidiabetic agents | Insulin receptor,Insulin-like growth factor 1 receptor |
1276 | Th1040 | Insulin Lispro | A chain:GIVEQCCTSICS Full view | 51 | Ia | Hormonal/Metabolic/genetic | Humalog KwikPen | Eli Lilly | Solution | Subcutaneous injection | Hypoglycemic Agents, Antidiabetic agents | Insulin receptor,Insulin-like growth factor 1 receptor |
1277 | Th1040 | Insulin Lispro | A chain:GIVEQCCTSICS Full view | 51 | Ia | Hormonal/Metabolic/genetic | Humalog Pen | Eli Lilly | N.A. | N.A. | Hypoglycemic Agents, Antidiabetic agents | Insulin receptor,Insulin-like growth factor 1 receptor |
1283 | Th1041 | Insulin Glargine | A-chain:GIVEQCCTSICS Full view | 53 | Ia | Hormonal/Metabolic/genetic | Lantus | Sanofi-Aventis | Solution | Subcutaneous injection | Hypoglycemic Agents, Antidiabetic agents | Insulin receptor,Insulin-like growth factor 1 receptor |
1284 | Th1041 | Insulin Glargine | A-chain:GIVEQCCTSICS Full view | 53 | Ia | Hormonal/Metabolic/genetic | Lantus OptiSet | N.A. | Solution | Subcutaneous injection | Hypoglycemic Agents, Antidiabetic agents | Insulin receptor,Insulin-like growth factor 1 receptor |
1285 | Th1041 | Insulin Glargine | A-chain:GIVEQCCTSICS Full view | 53 | Ia | Hormonal/Metabolic/genetic | Lantus SoloStar | N.A. | Solution | Subcutaneous injection | Hypoglycemic Agents, Antidiabetic agents | Insulin receptor,Insulin-like growth factor 1 receptor |
1324 | Th1045 | Imiglucerase | ARPCIPKSFGYSSVVCVCNA Full view | 255 | Ia | Metabolic | Cerezyme | Genzyme | Sterile, non-pyrogenic, white to off-white lyophilized product | Intravenous infusion | Enzyme Replacement Agents | Glucocerebroside |
1358 | Th1050 | Pegademase bovine | MAQTPAFNKPKVELHVHLDG Full view | 255 | Ia | Metabolic | Adagen | Enzon Inc. | Isotonic, pyrogen free, sterile solution, pH 7.2-7.4 | Intramusular Injection | Enzyme Replacement Agents | Adenosine,Growth factor receptor-bound protein 2 |
1361 | Th1051 | Human Serum Albumin | MKWVTFISLLFLFSSAYSRG Full view | 609 | Ia | Hematological/Metabolic/genetic | Albuminar | CSL Behring | Sterile aqueous solution of albumin obtained from large pools of adult human venous plasma by low temperature controlled fractionation according to the Cohn process. | Albumin (Human) 25%, Albuminar-25 (albumin human) , is to be administered by the Intravenous route. | Serum substitutes | N.A. |
1362 | Th1051 | Human Serum Albumin | MKWVTFISLLFLFSSAYSRG Full view | 609 | Ia | Hematological/Metabolic/genetic | Albutein | GRIFOLS | Sterile, aqueous solution for single dose intravenous administration containing 20% human albumin (weight/volume). | Albutein 20% is to be administered by the Intravenous route. | Serum substitutes | N.A. |
1382 | Th1060 | Insulin, porcine | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | vetsulin | Intervet Inc (Merck Animal Health) | Sterile injectable suspension in multidose vials containing 10 mL of 40 IU/mL porcine insulin zinc suspension | Subcutaneous Injection | Hypoglycemic Agents | Interferon alpha/beta receptor 2,Interferon alpha/beta receptor 1, Hyaluronan, Transforming growth factor beta-1 |
1422 | Th1071 | Pancrelipase | Pancreatic alpha amy Full view | 1206 | Ia | Metabolic/genetic/ | Pancrecarb | Digestive care US, Inc. | Delayed-Release Capsules, Buffered and Enteric-Coated Microspheres. | Oral route | Gastrointestinal Agents and Enzyme Replacement Agents | Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
1423 | Th1071 | Pancrelipase | Pancreatic alpha amy Full view | 1206 | Ia | Metabolic/genetic/ | Viokace | Aptalis Pharma US, Inc. | Beige-white amorphous powder, miscible in water and practically insoluble in alcohol and converted to tablet form | Oral route | Gastrointestinal Agents and Enzyme Replacement Agents | Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
1424 | Th1071 | Pancrelipase | Pancreatic alpha amy Full view | 1206 | Ia | Metabolic/genetic/ | ULTRESA | Aptalis Pharma US, Inc. | Beige-white amorphous powder, miscible in water and practically insoluble or insoluble in alcohol and ether and converted to Delayed-Release Capsules | Oral route | Gastrointestinal Agents and Enzyme Replacement Agents | Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
1425 | Th1071 | Pancrelipase | Pancreatic alpha amy Full view | 1206 | Ia | Metabolic/genetic/ | PERTZYE | Digestive care US, Inc. | Beige-white amorphous powder, miscible in water and practically insoluble or insoluble in alcohol and ether PERTZYE delayed-release capsule | Oral route | Gastrointestinal Agents and Enzyme Replacement Agents | Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
1426 | Th1071 | Pancrelipase | Pancreatic alpha amy Full view | 1206 | Ia | Metabolic/genetic/ | ULTRASE | Axcan Pharma | Capsules Enteric-Coated Microspheres | Oral route | Gastrointestinal Agents and Enzyme Replacement Agents | Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
1427 | Th1071 | Pancrelipase | Pancreatic alpha amy Full view | 1206 | Ia | Metabolic/genetic/ | ZENPEP | Aptalis Pharma US, Inc. | Delayed-Release Capsules | Oral route | Gastrointestinal Agents and Enzyme Replacement Agents | Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
1434 | Th1074 | Alglucerase | ARPCIPKSFGYSSVVCVCNA Full view | 497 | Ia | Metabolic | Ceredase | Genzyme Corporation | Clear sterile non-pyrogenic solution of alglucerase in a citrate buffered solution | Intravenous injection | Enzyme Replacement Agents | Plasminogen,Proteinase-activated receptor 1 |
1437 | Th1076 | Laronidase | APHLVQVDAARALWPLRRFW Full view | 626 | Ia | Metabolic | ALDURAZYME | Genzyme Corporation | Sterile, nonpyrogenic, colorless to pale yellow, clear to slightly opalescent solution that must be diluted prior to administration in 0.9% Sodium Chloride Injection | Intravenous infusion | Enzyme Replacement Agents | N.A. |
1453 | Th1083 | Coagulation Factor Ix | YNSGKLEEFVQGNLERECME Full view | 415 | Ia | Hematological/Metabolic/genetic | Alprolix | Biogen Idec Inc., and Genentech USA, Inc | Sterile, non-pyrogenic, preservative-free, white to off-white, lyophilized powder to cake for reconstitution with the provided diluent | Intravenous infusion | Coagulants and Thrombotic Agents | N.A. |
1455 | Th1085 | Agalsidase Beta | LDNGLARTPTMGWLHWERFM Full view | 398 | Ia | Metabolic | Fabrazyme | Genzyme Corp | Sterile, nonpyrogenic, white to off-white, lyophilized cake or powder for reconstitution with Sterile Water for Injection | N.A. | Enzyme Replacement Agents | N.A. |
1473 | Th1093 | Eculizumab | N.A. Full view | 0 | Ia | Haemetological | Soliris | Alexion, Inc | Sterile, clear, colorless, preservative-free 10 mg/mL solution for intravenous infusion | N.A. | N.A. | Complement C5 |
1476 | Th1096 | Idursulfase | SETQANSTTDALNVLLIIVD Full view | 525 | Ia | Metabolic | Elaprase | SHIRE | Sterile, nonpyrogenic clear to slightly opalescent, colorless solution that must be diluted prior to administration in 0.9% Sodium Chloride Injection, USP | Intravenous infusion | Enzyme Replacement Agents | Dermatan sulfate,Heparan sulfate,Perilipin-3 |
1482 | Th1100 | Pramlintide | KCNTATCATQRLANFLVHSS Full view | 37 | Ia | Hormonal/Metabolic | Symlin | Amylin Pharmaceuticals (now a wholly owned subsidiary of AstraZeneca) | Clear, isotonic, sterile solution | Subcutaneous injection | N.A. | Calcitonin receptor,Receptor activity-modifying protein 1,Receptor activity-modifying protein 2,Receptor activity-modifying protein 3 |
1494 | Th1101 | Galsulfase | SGAGASRPPHLVFLLADDLG Full view | 497 | Ia | Metabolic | Naglazyme | BioMarin | Sterile, nonpyrogenic, colorless to pale yellow, clear to slightly opalescent solution that must be diluted with 0.9% Sodium Chloride Injection, USP, prior to administration | Intravenous infusion | Enzyme Replacement Agents | Dermatan sulfate,Perilipin-3 |
1502 | Th1105 | Insulin Aspart | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | NovoLog | Novo Nordisk | Sterile, aqueous, clear, and colorless solution | Subcutaneous injection, Intravenous injection | Hypoglycemic Agents and Antidiabetic Agents | Insulin receptor |
1503 | Th1105 | Insulin Aspart | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | NovoLog Mix 50/50 | Novo Nordisk | Uniform, white, sterile suspension that contains insulin aspart | Subcutaneous injection | Hypoglycemic Agents and Antidiabetic Agents | Insulin receptor |
1504 | Th1105 | Insulin Aspart | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | NovoLog Mix 70/30 | Novo Nordisk | Uniform, white, sterile suspension that contains insulin aspart 100 Units/mL. | Subcutaneous injection | Hypoglycemic Agents and Antidiabetic Agents | Insulin receptor |
1511 | Th1106 | Insulin Detemir | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | LEVEMIR | Novo Nordisk | Clear, colorless, aqueous, neutral sterile solution | Subcutaneous injection | Antidiabetic Agents | Insulin receptor |
1602 | Th1128 | Velaglucerase Alfa | ARPCIPKSFGYSSVVCVCNA Full view | 497 | Ia | Hormonal | VPRIV | Shire | Sterile, preservative free, lyophilized powder | Intravenous infusion | Enzymes | Glucosylceramidase |